Optometry Times Staff Reports

The launch is supported by results from a phase 3 randomized, double-masked, placebo-controlled trial (3-02).

The analysis included 12,183,254 patients, with 304,823 identified as smokers and 11,878,431 as non-smokers.

The trial is evaluating AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction.

The analysis included studies 31 studies identified through Web of Science, PubMed, CNKI, and Wanfang databases through October 2025.

The decision lengthens the approved treatment period outlined in the prescribing information and may lessen the need to change therapies for patients who continue to show a lasting response.

The TECNIS Eyhance IOL is part of the TECNIS platform, which Johnson & Johnson said has been used in ophthalmology for more than 25 years.

The survey also examined interest in elective procedures such as LASIK.

The study demonstrates that Corynebacterium mastitidis, a bacterium that resides on the ocular surface, can be genetically modified to secrete the anti-inflammatory cytokine interleukin-10.

AlloSpan Canal is designed to address limitations associated with existing approaches by combining nitinol-guided canaloplasty with biological reinforcement.

Corticosteroids remain a cornerstone of postoperative management.

The formulation combines 2 pharmacologic agents: carbachol, a direct-acting cholinergic agonist, and brimonidine tartrate, an α-2 adrenergic receptor agonist.

Phase 2 ArMaDa data show statistically significant 31% reduction in geographic atrophy lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

China clears first mite-targeting drop for Demodex blepharitis, bringing Xdemvy-style relief and new options beyond lid scrubs and tea tree oil.

The study was carried out between July 8 and August 1, 2024, and included 127 eyes from 68 children aged 8–14 years.

The prospective, multicenter study enrolled 318 patients across 20 US sites.

The findings were presented at the 51st Annual Meeting of AAPOS in Boston, Massachusetts.

The expansion follows a 30% year-over-year growth rate.

Chiesi Global Rare Diseases said the agency declined to approve its application and requested additional information for the proposed treatment of Leber hereditary optic neuropathy.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED.

According to the company, the lens is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity.

The study highlights the broader impact of OR on patients’ quality of life.

Amniotic membrane therapy has been used in refractory cases to protect the ocular surface, modulate inflammation and fibrosis, and promote epithelial healing.

The review notes aesthetic considerations are increasingly important as social media and video conferencing spotlight facial appearance.

Researchers examined 3 primary associations: the risk of developing uveitis following an IMID diagnosis, the odds of having a prior IMID among uveitis patients, and the risk of developing an IMID after a uveitis diagnosis.

The company said the expansions support its goal of making evidence-based myopia management accessible to eye care professionals and children worldwide.

The clinical study will evaluate a noninvasive corneal strengthening procedure designed to reshape the cornea and correct refractive errors in-office without tissue removal.